跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NK (CD20)
首页
药物
NK (CD20)
NK (CD20)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER
EP 3523331 A1
申请人: NOVARTIS AG
优先权: 2016
CN
EP
US
WO
13 件公开
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US 10272083 B2
申请人: ACERTA PHARMA BV
优先权: 2015
US
9 件公开
TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY
EP 4262830 A4
申请人: ARTIVA BIOTHERAPEUTICS INC
优先权: 2020
EP
US
WO
3 件公开
EX VIVO NK CELL DIFFERENTIATION FROM CD34+ HEMATOPOIETIC CELLS
US 2015010583 A1
申请人: SPANHOLTZ JAN
优先权: 2012
US
2 件公开
Anti-CD20 combination for tumor treatment
CN 106943596 A
申请人: BIRDIE BIOTECH INC
优先权: 2016
CN
2 件公开
Cancer and B-cell related disease therapy
US 12325754 B2
申请人: UNIV SOUTHAMPTON
优先权: 2016
US
Specific antibody with CD20 as target, CAR-NK cell and preparation and application of CAR-NK cell
CN 108285486 A
申请人: ZHEJIANG ASCLEPIUS TECH COMPANY
优先权: 2018
CN
EXPANDED NK CELL FRACTIONS FOR TRANSPLANTATION IN COMBINATION THERAPY
CN 113853204 A
申请人: GAMIDA CELL LTD
优先权: 2019
CN
Composition of NK cells and CD20+ target antibodies and application thereof in lymphoma
CN 110292630 A
申请人: ANHUI RUIDA HEALTH IND CO LTD
优先权: 2019
CN
Treatment of tumors with NK cells and antibodies targeting CD20
CN 117529327 A
申请人: ADIVA BIOTHERAPEUTICS INC
优先权: 2021
CN
第 1 / 3 页
上一页
下一页
药物
反馈